Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).
Michael Choi, MD, discusses key mechanistic differences between BTK degraders and BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia, , as well as highlights how this approach could address unmet needs within the CLL treatment paradigm.
Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.